Clinical and economic challenges facing pharmacogenomics

[1]  R. Palmer,et al.  Crizotinib--latest champion in the cancer wars? , 2010, The New England journal of medicine.

[2]  Peter J Neumann,et al.  Personalized medicine: factors influencing reimbursement. , 2010, Health policy.

[3]  Howard L McLeod,et al.  Economic opportunities and challenges for pharmacogenomics. , 2010, Annual review of pharmacology and toxicology.

[4]  S. Tunis,et al.  Does comparative-effectiveness research threaten personalized medicine? , 2009, The New England journal of medicine.

[5]  D. Paci,et al.  Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine , 2009 .

[6]  L. Garrison,et al.  Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals , 2009, Journal of managed care pharmacy : JMCP.

[7]  B. Schackman,et al.  Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer , 2009, Cancer.

[8]  Muin J. Khoury,et al.  Challenges of translating genetic tests into clinical and public health practice , 2009, Nature Reviews Genetics.

[9]  P. Deverka.  Pharmacogenomics, Evidence, and the Role of Payers , 2009, Public Health Genomics.

[10]  Muin J. Khoury,et al.  The evidence dilemma in genomic medicine. , 2008, Health affairs.

[11]  L. Mantovani,et al.  An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  Shashi Amur,et al.  Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.

[13]  Bethan Hughes.  Novel risk-sharing scheme puts the spotlight on biomarkers , 2007, Nature Reviews Drug Discovery.

[14]  L. Lesko,et al.  Personalized Medicine: Elusive Dream or Imminent Reality? , 2007, Clinical pharmacology and therapeutics.

[15]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.

[16]  D. Cunningham,et al.  Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment , 2007, British Journal of Cancer.

[17]  Reginald D Williams,et al.  Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy. , 2006, Health affairs.

[18]  K. Phillips.  The intersection of biotechnology and pharmacogenomics: health policy implications. , 2006, Health affairs.

[19]  John R Ridge.  Reimbursement and coverage challenges associated with bringing emerging molecular diagnostics into the personalized medicine paradigm. , 2006, Personalized medicine.

[20]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[21]  J. Sanderson,et al.  Typing TPMT and ITPase to detect azathioprine toxicity. , 2006, Personalized medicine.

[22]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[23]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[24]  Kathryn A Phillips,et al.  A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. , 2004, Pharmacogenomics.

[25]  J. Woodcock,et al.  Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective , 2004, Nature Reviews Drug Discovery.

[26]  G. Giaccone.  The Role of Gefitinib in Lung Cancer Treatment , 2004, Clinical Cancer Research.

[27]  Jai Shah.  Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare , 2003, Nature Biotechnology.

[28]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[29]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[30]  J. Teagarden,et al.  Comparative Effectiveness Research and Personalized Medicine , 2012, PharmacoEconomics.

[31]  T. Bodenheimer,et al.  Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? , 2009, Health affairs.